Table 4.
Analysis of top findings stratified by gemfibrozil use. Models adjusted for age at statin use, sex, and race.
| Concomitant gemfibrozil use | No gemfibrozil use | |||||||
|---|---|---|---|---|---|---|---|---|
| Minor allele frequency Controls (n=5) |
Minor allele frequency Cases (n=118) |
Odds ratio (95% confidence interval) |
p- value |
Minor allele frequency Controls (N=716) |
Minor allele frequency Cases (N=65) |
Odds ratio (95% confidence interval) |
p-value | |
| RYR2 | ||||||||
| rs2819742 | 0.50 | 0.27 | 0.47 (0.12, 1.88) | 0.29 | 0.378 | 0.269 | 0.52 (0.34, 0.80) | 0.003 |
| Interaction p-value = 0.44 | ||||||||
| SLCO1B1 | ||||||||
| rs4149056 | 0.30 | 0.22 | 0.68 (0.24 to 1.98) | 0.49 | 0.136 | 0.277 | 2.45 (1.61 to 3.75) | 3.11E-05 |
| Interaction p-value = 0.02 | ||||||||
| SLCO1B1 | ||||||||
| rs4149033 | 0.40 | 0.22 | 0.41 (0.07 to 2.25) | 0.30 | 0.213 | 0.354 | 2.17 (1.47 to 3.21) | 1.08E-04 |
| Interaction p-value = 0.03 | ||||||||